Danaher Corporation (DHR) has a MoatMap StockRank of 56/100 based on Quality (58/100), Value (34/100), and Momentum (48/100) factor scores. The current signal is HOLD. Danaher is the ultimate 'picks-and-shovels' quality compounder for the biologics and CDMO industries. Through Cytiva and Pall, it controls the indispensable consumables required for biologic manufacturing, boasting high switching costs and an un-copyable moat. As the bioprocessing inventory destocking cycle inflects, Danaher's high-margin recurring revenue will drive massive operating leverage, creating a highly asymmetric risk-reward profile.
Danaher Corporation is a global diversified science and technology innovator operating in Biotechnology, Life Sciences, and Diagnostics, providing analytical instruments, reagents, and services. It benefits from a diversified portfolio of market-leading brands and proprietary technologies in mission-critical scientific and healthcare fields. Its Danaher Business System (DBS) drives operational excellence, innovation, and strategic acquisitions, making it a highly acquisitive conglomerate focused on high-growth segments.
| Price | $186.64 |
| Market Cap | $127.8B |
| P/E (TTM) | 36.24 |
| P/E (Forward) | 20.51 |
| Price/Book | 2.49 |
| Return on Equity | 7.1% |
| Return on Invested Capital | 5.9% |
| Debt/Equity | 37.17 |
| Gross Margin | 59.0% |
| Operating Margin | 22.9% |
| Revenue Growth | 3.7% |
| Dividend Yield | 0.9% |
| Free Cash Flow | $4.6B |
Danaher Corporation operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).